» Articles » PMID: 37893564

Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 MmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study

Abstract

: Arterial hypertension (HTN) is the leading preventable cause of atherosclerotic cardiovascular diseases (ASCVD) and death from all causes. This study aimed to determine the prevalence rates of HTN diagnosed according to the threshold diagnostic criteria 130/80 mmHg and 140/90 mmHg, to compare blood pressure (BP) control, and to evaluate their associations with cardiovascular diseases and cardiometabolic and renal risk factors. : This was a cross-sectional observational study conducted in primary care with a population-based random sample: 6588 people aged 18.0-102.8 years. Crude and adjusted prevalence rates of HTN were calculated. BP control was compared in HTN patients with and without ASCVD or chronic kidney disease (CKD). Their associations with cardiovascular diseases and cardiometabolic and renal factors were assessed using bivariate and multivariate analysis. : Adjusted prevalence rates of HTN diagnosed according to 140/90 and 130/90 criteria were 30.9% (32.9% male; 29.7% female) and 54.9% (63.2% male; 49.3% female), respectively. BP < 130/80 mmHg was achieved in 60.5% of HTN patients without ASCVD or CKD according to 140/90 criterion, and 65.5% according to 130/80 criterion. This BP-control was achieved in 70% of HTN patients with ASCVD and 71% with CKD, according to both criteria. Coronary heart disease (CHD), heart failure, atrial fibrillation, stroke, diabetes, prediabetes, low glomerular filtration rate (eGFR), hyperuricemia, hypercholesterolemia, obesity, overweight, and increased waist-to-height ratio were independently associated with HTN according to both criteria. : Almost a third of the adult population has HTN according to the 140/90 criterion, and more than half according to the 130/90 criterion, with a higher prevalence in men. The main clinical conditions associated with HTN were heart failure, diabetes, CHD, low eGFR, and obesity.

Citing Articles

Novel Techniques, Biomarkers and Molecular Targets to Address Cardiometabolic Diseases.

Di Fiore V, Cappelli F, Punta L, De Biase N, Armenia S, Maremmani D J Clin Med. 2024; 13(10).

PMID: 38792427 PMC: 11122330. DOI: 10.3390/jcm13102883.

References
1.
Del Pinto R, Giua C, Keber E, Grippa E, Tilotta M, Ferri C . Impact of 2021 ESC Guidelines for Cardiovascular Disease Prevention on Hypertensive Patients Risk: Secondary Analysis of Save Your Heart Study. High Blood Press Cardiovasc Prev. 2023; 30(2):167-173. PMC: 10090023. DOI: 10.1007/s40292-023-00568-3. View

2.
. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304):957-980. PMC: 8446938. DOI: 10.1016/S0140-6736(21)01330-1. View

3.
Banegas J, Navarro-Vidal B, Ruilope L, de la Cruz J, Lopez-Garcia E, Rodriguez-Artalejo F . Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment. Circ Cardiovasc Qual Outcomes. 2015; 8(1):67-76. DOI: 10.1161/CIRCOUTCOMES.114.001191. View

4.
Atasoy S, Middeke M, Johar H, Peters A, Heier M, Ladwig K . Cardiovascular mortality risk in young adults with isolated systolic hypertension: findings from population-based MONICA/KORA cohort study. J Hum Hypertens. 2021; 36(12):1059-1065. PMC: 9734041. DOI: 10.1038/s41371-021-00619-z. View

5.
Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View